Development, manufacture and trade of APIs (molecular clones) for biologics, biosimilars and biobetters.
Our technologies reach different levels of development and some of our products are ready to be tech-transferred. Implementation and fine-tuning are available at the manufactor’s (GMP, pharma-grade) site.
We recruit the best scientists and technologies in Switzerland and across Europe.
We believe in the current biologic therapy and aim to develop immunotherapy treatments involving the upcoming technologies of cell therapy such as TIL and CAR-T.
Biologics / Chimeric mAb / Biosimillar
Manufacture the genetically modified cell line while setting the production sights to bolster pipelines and manufacture Biobetters.
Maintain the market share for the company’s soon to be off-patent reference products.
Extrapolation framework in order to turn off-label determinations into off-label use
Rich portfolio (14 products) of manufacturing processes for biosimilars, including anti-cancer and anti-inflammatory mAbs and hormones.
Currently two mAbs are ready at the commercial scale.
In addition we focus on the extrapolation into off-label use (e.g. Adalimumab)
